Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Trading Down 8.0 %

NASDAQ:EXAS opened at $43.05 on Wednesday. Exact Sciences has a one year low of $35.34 and a one year high of $108.99. The business's 50-day simple moving average is $44.30 and its 200 day simple moving average is $58.46. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.23 and a current ratio of 2.48. The stock has a market cap of $7.62 billion, a price-to-earnings ratio of -10.18 and a beta of 1.32.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Evercore ISI increased their price target on shares of Exact Sciences to $65.00 in a research note on Tuesday. Cowen reduced their target price on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a report on Wednesday, August 3rd. Cowen dropped their price target on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a research note on Wednesday, August 3rd. Craig Hallum reduced their price objective on Exact Sciences from $81.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, August 3rd. Finally, Piper Sandler assumed coverage on shares of Exact Sciences in a research report on Thursday, June 2nd. They set a "neutral" rating and a $50.00 target price for the company. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Exact Sciences currently has an average rating of "Moderate Buy" and an average price target of $71.00.

Insider Buying and Selling at Exact Sciences

In other news, Director Katherine S. Zanotti sold 1,086 shares of the firm's stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now owns 60,318 shares of the company's stock, valued at $2,420,561.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the company's stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the sale, the director now owns 60,318 shares in the company, valued at $2,722,754.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the transaction, the director now owns 60,318 shares of the company's stock, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Insiders have sold a total of 5,701 shares of company stock valued at $251,872 in the last three months. Corporate insiders own 1.30% of the company's stock.